tiprankstipranks
Trending News
More News >
Lixte Biotechnology Holdings (LIXT)
NASDAQ:LIXT
US Market

Lixte Biotechnology Holdings (LIXT) Income Statement

Compare
97 Followers

Lixte Biotechnology Holdings Income Statement

Last quarter (Q3 2025), Lixte Biotechnology Holdings's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Lixte Biotechnology Holdings's net income was $-2.03M. See Lixte Biotechnology Holdings’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 3.57M$ 5.09M$ 6.31M$ 6.72M$ 3.27M
Depreciation and Amortization
$ 0.00$ 0.00$ 0.00$ 0.00$ 3.27M
EBITDA
$ -3.57M$ -5.07M$ -6.30M$ -6.72M$ 0.00
Operating Income
$ -3.57M$ -5.09M$ -6.31M$ -6.72M$ -3.27M
Other Income/Expenses
$ -13.18K$ 3.21K$ -1.05K$ -7.95K$ 1.56K
Pretax Income
$ -3.59M$ -5.09M$ -6.31M$ -6.73M$ -3.26M
Net Income
$ -3.59M$ -5.09M$ -6.31M$ -6.73M$ -3.26M
Per Share Metrics
Basic EPS
$ -1.59$ -2.66$ -4.00$ -5.00$ -2.89
Diluted EPS
$ -1.59$ -2.66$ -4.00$ -5.00$ -2.89
Weighted Average Shares Outstanding
2.25M 1.91M 1.58M 1.35M 1.13M
Weighted Average Shares Outstanding (Diluted)
2.25M 1.92M 1.58M 1.35M 1.13M
Currency in USD

Lixte Biotechnology Holdings Earnings and Revenue History